Vaccinations

University of Oxford launches first human aerosol TB vaccine trial

The University of Oxford has commenced a new clinical trial called TB-45, which will test the safety of a new tuberculosis (TB) vaccine.

UKHSA highlights priority pathogens for public health research and development

The UK Health Security Agency (UKHSA) has released a new tool that will help research and development efforts of diagnostics, vaccines, and treatments for pathogens that pose the greatest risk to public health.

Uganda start vaccine trials and experimental treatments for Sudan Virus Disease after outbreak

Sudan Virus Disease (SVD), a deadly illness related to ebola, has become a serious public health threat in Uganda.

Why immunisation matters for healthy ageing

ILC is the UK’s leading authority on the impact of longevity on society, combining evidence, solutions and networks to make change happen. We hear...

Unlocking the full value of life-course immunization: A key to sustainable healthcare

An ageing population, rising antimicrobial resistance, and the ongoing threat of infectious and chronic diseases are placing immense pressure on our societies. A shift to a preventative approach is necessary for the efficiency and sustainability of our healthcare systems. Central to this shift is the often-underutilized tool of life-course immunization.

Researchers find new anti-malaria antibodies bring hope for prevention

Researchers have made a new discovery in the fight against malaria. The study, recently published in Science, identified a new class of antibodies targeting a previously unexplored malaria parasite region.

UK government strengthen their pandemic preparedness with H5 influenza vaccine

In the possible event of a pandemic, the UK has secured 5 million doses of an H5 influenza vaccine to stay one step ahead of the avian influenza virus.

Global measles cases surge in 2023: What does the future hold?

In 2023, the world saw an increase in measles cases, with an estimated 10.3 million people infected, showing a 20% rise from the previous year.

Less talk, more action on medical countermeasures

Dr Ayoade Alakija, humanitarian leader, WHO Special Envoy for the ACT-Accelerator, Chair of FIND and Co-Chair of the G7 Impact Investment Initiative on Global Health, outlines the negative effects of vaccine nationalism and emphasizes the importance of countries collaborating to enhance preparedness and medical countermeasures in the face of public health threats.

The challenges facing vaccination in fragile and conflict-affected settings

Sian Williams, Senior Policy Adviser for Child Health at the UK Committee for UNICEF (UNICEF UK), explains the barriers to childhood vaccination and the health consequences of missed immunisations.

Vaccine-preventable cancers through cooperation

Milena Angelova, EESC member and Rapporteur for the EESC opinion on Vaccine-preventable cancers, highlights the vital role of civil society in eradicating them.

Two-step vaccination shows promise against influenza

A groundbreaking new two-step vaccination strategy tested on pigs shows promise in the fight against influenza.

The importance of cold chain management for maintaining vaccines

Dr Nenad Miljković, President-elect of the European Association of Hospital Pharmacists (EAHP), outlines the critical role of cold chain management in maintaining the efficacy and safety of vaccines.

Promoting awareness of neglected tropical diseases

Open Access Government discusses the prevalence of neglected tropical diseases, including barriers to awareness and the need to scale up effective interventions.

New vaccine program in Wales targets respiratory infection in vulnerable groups

Wales is set to introduce a vaccination program aimed at protecting vulnerable populations from a common but potentially severe respiratory infection known as Respiratory Syncytial Virus (RSV).

New study shows how some individuals avoid COVID-19

Researchers from the Wellcome Sanger Institute, University College London (UCL), and Imperial College London have revealed insights into why some people remain unscathed despite exposure to SARS-CoV-2, the virus responsible for COVID-19.

HIV vaccine candidate shows early success in clinical trial

An HIV vaccine candidate developed at the Duke Human Vaccine Institute has demonstrated the ability to trigger low levels of a rare type of neutralising antibodies (bnAbs) in a small group of participants.

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders